Craig Gracey, who serves as the Chief Accounting Officer at Omada Health, Inc. (OMDA), recently completed a set of transactions involving the company's common equity. On June 12, 2026, Gracey offloaded shares totaling $120,123 in value. Simultaneously, he acquired shares through the exercise of stock options, which were valued at $41,062.
The divestment portion of the transaction involved the sale of 6,894 shares of common stock. These shares were sold at a weighted average price of $17.4243. The individual sales occurred within a price range spanning from $17.04 to $17.71. This sale was executed under a pre-arranged 10b5-1 trading plan that Gracey adopted on March 13, 2026. The timing of these trades coincides with a period of significant upward momentum for Omada shares. The stock currently trades at $22.98 and has delivered a 49% return over the past six months.
Before the sale, Gracey acquired 6,250 shares of common stock by exercising stock options at a price of $6.57 per share. This exercise transaction was part of a same-day exercise-and-sale process. The activity was reported in an amended filing to correct an inadvertent omission from an earlier report. The options exercised were part of a grant where 25% vested on the first anniversary of September 9, 2024, with monthly vesting thereafter. The options have an expiration date of October 23, 2034.
Following these transactions, Gracey directly owns 15,441 shares of Omada Health, Inc. common stock. He also holds 43,750 derivative shares in the form of stock options. While the company was not profitable over the last twelve months, analysts forecast a turnaround with expected earnings of $0.34 per share in 2026. According to InvestingPro analysis, the stock appears overvalued at current levels relative to its Fair Value estimate, placing it among companies on the Most Overvalued list.
In other recent news, Omada Health Inc. reported its financial results for the first quarter of 2026, showing an earnings per share (EPS) of -$0.05, which exceeded the anticipated -$0.08. The company's revenue reached $78 million, representing a 42% increase compared to the previous year. These financial results have contributed to a positive outlook among investors. Additionally, Citizens raised its price target for Omada Health to $21 from $18, maintaining a Market Outperform rating. Analyst Constantine Davides highlighted that the company's stock recently traded at 2.5 times the 2026 revenue estimate.
In other developments, Omada Health held its 2026 Annual Meeting of Stockholders, where Sean Duffy and Trevor Fetter were elected as Class I Directors. Both directors will serve until the 2029 annual meeting. These recent developments reflect the company's strong financial performance and positive market sentiment.